United Therapeutics price target raised to $600 from $525 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on United Therapeutics (UTHR) to $600 from $525 and keeps a Buy rating on the shares. United Therapeutics announced development of a soft mist inhaler version of treprostinil, expected to launch in 2027 for Pulmonary Arterial Hypertension and PH-ILD, which is likely to pressure Tyvaso DPI but serve as a strategic evolution to defend share against entrants like Yutrepia rather than disrupt the DPI market entirely, the analyst tells investors in a research note. With upcoming Phase 3 readouts for ralinepag and Tyvaso in IPF and three anticipated launches, management reiterated its goal of a $4B revenue run rate by 2H27, with potential upside beyond that target, the firm says.